Clinical Trials

Now Enrolling

It is not the intention of the Cholangiocarcinoma Foundation to provide specific medical advice.  We provide website users with information to help them better understand their health conditions and the current approaches related to prevention, diagnosis, treatment and supportive care. You are urged to always seek the advice of your physician or other qualified healthcare provider.

A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy

Study Name   A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy ClinicalTrials.gov Identifier (if applicable)   NCT02150967 Study Center Institution Name   Novartis Pharmaceuticals Institution Address   One Health Plaza City   East Hanover State   New Jersey Zip Code   07936 Phone   (888) 669-6682 Website   https://www.novartis.com/ Study Contacts Principal Investigator   TBD P.I. Phone   (888) 669-6682 P.I. Email   novartis.email@novartis.com List additional Principal Investigators (include phone number and email)   Please refer to the Clinical Trials.gov listing and contact Novartis at 1-888-669-6682 for a research center near you Study Coordinator   TBD Study Coordinator Phone  ... read more

Ceramide NanoLiposome in Patients with Advanced Solid Tumors

Study Name   Ceramide NanoLiposome in Patients with Advanced Solid Tumors ClinicalTrials.gov Identifier (if applicable)   NCT02834611 Study Center Institution Name   University of Maryland, Greenebaum Cancer Center Institution Address   22 South Greene Street City   Baltimore State   Maryland Zip Code   21201 Phone   (800) 492-5538 Website   http://www.umm.edu/programs/cancer List additional Institutions (include address, phone number, and website)   Medical University of South Carolina, Hollings Cancer Center 86 Jonathan Lucas Street Charleston, SC 29425 843-792-9300 http://www.hollingscancercenter.org/index.html University of Virginia, Emily Couric Clinical Cancer Center 1240 Lee Street Charlottesville, VA 22903 434-924-9333 https://uvahealth.com/locations/profile/emily-couric-clinical-cancer-center Study Contacts Principal Investigator   Edward Sausville, MD, PhD P.I. Phone   (800) 492-5538 P.I. Email   cheryl.young@umm.edu List additional Principal Investigators (include phone number and email)   Carolyn... read more

ClarIDHy: A Phase 3, multicenter, randomized, double-blind of orally administered AG-120 for patients with advanced cholangiocarcinoma and an IDH1 gene mutation.

Study Name ClarIDHy: A Phase 3, multicenter, randomized (people are allocated by chance to receive one of clinical interventions) double-blind (neither the participant nor the investigator know who is receiving AG-120 or the placebo) of orally administered AG-120 for patients with advanced cholangiocarcinoma and an IDH1 gene mutation. Patients who are allocated to the placebo group and experience disease progression are eligible to receive AG-120. ClinicalTrials.gov Identifier (if applicable) NCT02989857 Study Center Institution Name Agios (study sponsor) Institution Address 88 Sidney Street City Cambridge State Massachusetts Zip Code 02139 Phone (617) 649-8600 Website http://www.ClarIDHy.com List additional Institutions (include address, phone number, and website) Fox Chase Cancer Center, Philadelphia, PA, United States MD Anderson Cancer Center, Houston, TX, United States Memorial Sloan Kettering Cancer Center,... read more

A Phase 2 Open-Label Study in Patients with Cholangiocarcinoma

Study Name   A Phase 2 Open-Label Study in Patients with Cholangiocarcinoma ClinicalTrials.gov Identifier (if applicable)   NCT02924376 Study Center Institution Name   Incyte Corporation Institution Address   1801 Augustine Cut-Off City   Wilmington State   Delaware Zip Code   19803 Phone   (855) 463-3463 Study Contacts Principal Investigator   A lead investigator has not been identified yet (TBD) P.I. Phone   (855) 463-3463 P.I. Email   TBD@XYZ.com List additional Principal Investigators (include phone number and email)   Please refer to the Clinical Trials.gov listing and contact the Incyte Help Line at 855-463-3463 for a research center near you. Study Coordinator   TBD Study Coordinator Phone   (855) 463-3463 Study Coordinator Email   TBD@XYZ.com List additional Study Coordinators (include phone number and email)  ... read more

Immunotherapy of Cholangiocarcinoma

Study Name Immunotherapy of cholangiocarcinoma ClinicalTrials.gov Identifier (if applicable) https://clinicaltrials.gov/ct2/show/NCT03042182 Study Center Institution Name Immunitor LLC Institution Address 25 peace Avenue City Ulaanbaatar Country Mongolia Phone (301) 476-0930 Website http://www.immunitor.com Study Contacts Principal Investigator Aldar Bourinbaiar P.I. Phone (301) 476-0930 P.I. Email immunitor@gmail.com Study Coordinator Immunitor LLC Study Coordinator Phone (917) 326-9508 Study Coordinator Email info@immunitor.com List additional Study Coordinators (include phone number and email) Presently this study is conducted in Mongolia only. Patients must temporarily reside in Ulaanbaatar for treatment and follow up visits. OVERVIEW – in layman’s terms (150 words max) Earlier version of immunotherapy, which was designed for patients with hepatocellular carcinoma (HCC) has shown limited efficacy in patients with cholangiocarcinoma (CCA). The decline in levels of CA19.9 marker common in... read more

Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors

Study Name   Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors ClinicalTrials.gov Identifier (if applicable)   https://www.clinicaltrials.gov/ct2/show/NCT02746081?term=IDH1&rank=6 Study Center Institution Name   USC Norris Comprehensive Cancer Center Institution Address   1441 Eastlake Ave City   Los Angeles State   California Zip Code   90089 Phone   (323) 865-3967 Website   http://www.uscnorris.com Study Contacts Principal Investigator   Heinz Josef Lenz P.I. Phone   (323) 865-3967 P.I. Email   lenz@usc.edu Study Coordinator   Jubilee Acap Study Coordinator Phone   (323) 865-3900 Study Coordinator Email   jubilee.acap@med.usc.edu OVERVIEW – in layman’s terms (150 words max)   An Open-label, Non-Randomized (the participants are not assigned by chance to different treatment groups), Multi-center, Phase I Study. Phase II Dose of the Orally taken Mutant IDH... read more

My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents

Study Name   My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents ClinicalTrials.gov Identifier (if applicable)   NCT02091141 Study Center Institution Name   Science 37 Inc. Institution Address   5875 Green Valley Circle, Suite 100 City   Culver City State   California Zip Code   90230 Phone   (720) 207-8363 Website   https://www.science37.com/ Study Contacts Principal Investigator   David Chan, MD P.I. Phone   (213) 529-0657 P.I. Email   mypathway@science37.com Study Coordinator   Jade Yen Study Coordinator Phone   (213) 529-0657 Study Coordinator Email   jade@science37.com OVERVIEW – in layman’s terms (150 words max)   This open-label study... read more

Phase II study of copanlisib (BAY 80-6946) in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma

Study Name   Phase II study of copanlisib (BAY 80-6946) in combination with gemcitabine and cisplatin in advanced cholangiocarcinoma Study Center Institution Name   Moffitt Cancer Center Institution Address   12902 Magnolia Drive City   Tampa State   Florida Zip Code   33612 Study Contacts Principal Investigator   Richard Kim, MD P.I. Phone   (813) 745-1277 P.I. Email   richard.kim@moffitt.org Study Coordinator   Fatima Tariq Study Coordinator Phone   (813) 745-1277 Study Coordinator Email   fatima.tariq@moffitt.org OVERVIEW – in layman’s terms (150 words max)   This is a study for patients with advanced cholangiocarcinoma or gallbladder cancer. It includes chemotherapy (gemcitabine and cisplatin) with the addition of a PI3K inhibitor to try to improve outcome for this group of patients Enrollment   25 Study... read more

A Phase II Study of Nivolumab in Patients with Advanced Refractory Biliary Cancers

Study Name   A Phase II Study of Nivolumab in Patients with Advanced Refractory Biliary Cancers Study Center Institution Name   Moffitt Cancer Center Institution Address   12902 Magnolia Drive City   Tampa State   Florida Zip Code   33606 Website   https://www.moffitt.org Study Contacts Principal Investigator   Nishi Kothari, MD P.I. Phone   (813) 745-7229 P.I. Email   nishi.kothari@moffitt.org Study Coordinator   Marjorie Brelsford Study Coordinator Phone   (813) 745-6704 Study Coordinator Email   Marjorie.Brelsford@moffitt.org OVERVIEW – in layman’s terms (150 words max)   The purpose of this study is to test the efficacy of the immunotherapy agent nivolumab in patients with advanced, refractory biliary cancers (intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer). Patients will be evaluated for progression-free survival, overall survival and... read more

STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors (including cholangiocarcinoma) that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Study Name STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors(including cholangiocarcinoma) that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements ClinicalTrials.gov Identifier (if applicable) NCT02568267 Study Center Institution Name This is a multicenter, global trial enrolling patients with solid tumors (including cholangiocarcinoma). Please visit www.STARTRKtrials.com, or contact Ignyta at 1-844-STARTRK (782-7875) or via email at STARTRKtrials@ignyta.com to find a participating study center near you. Institution Address Ignyta Inc. City San Diego State California Zip Code 92121 Phone (844) 782-7875 Website https://www.STARTRKtrials.com/ List additional Institutions (include address, phone number, and website) This is a multicenter, global trial. Please visit www.STARTRKtrials.com, or contact Ignyta at 1-844-STARTRK (782-7875) or via email at STARTRKtrials@ignyta.com... read more

ClinicalTrials.gov

ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world.

Search for term Cholangiocarcinoma

Search for term Bile Duct Cancer

Search for term Solid Tumor

Pin It on Pinterest